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Respiratory syncytial virus (RSV) infection has been shown to be a risk factor for the development of allergy
in humans and mice. The allergy-enhancing properties of RSV may be dependent on atopic background and
an individual’s history of RSV infection. We examined the influence of the timing of infection and prior
inoculation with RSV in a mouse model of allergic asthma. Mice were sensitized to and challenged with
ovalbumin (OVA) and were inoculated with RSV either before or during the sensitization or challenge period.
One group of mice was inoculated with RSV both before sensitization to OVA and during challenge with OVA.
Increased pulmonary expression of interleukin (IL)–4, IL-5, and IL-13 mRNA and aggravated alveolitis and
hypertrophy of mucus-producing cells were observed only when OVA-sensitized mice were inoculated with
RSV shortly before or during challenge with OVA. Despite protection against viral replication, prior inoculation
with RSV did not abrogate RSV-enhanced, OVA-induced expression of T helper 2 (Th2) cytokines in the lung.
In conclusion, inoculation with RSV enhances allergic disease only when the immune system has already been
Th2-primed by the allergen (i.e., OVA). This RSV-enhanced allergy is not completely abrogated by prior in-
oculation with RSV.
Respiratory syncytial virus (RSV), a member of the fam-
ily Paramyxoviridae, genus Pneumovirinae, is the most
common cause of respiratory-tract infections in young
children [1]. The clinical presentation can vary, from
mild upper respiratory–tract illness to severe bronchi-
olitis and pneumonia [2]. Epidemiological data show
that almost all children become infected with RSV dur-
ing their first or second year of life and that the inci-
dence of RSV bronchiolitis reaches a maximum at the
age of 2 months [3]. Because severe RSV infection in-
duces asthmalike symptoms (e.g., wheezing and airway
hyperreactivity [AHR]), studies have been performed to
investigate the effect of RSV bronchiolitis on the devel-
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opment of respiratory allergy and asthma in children.
Thus far, controversial results have been reported [4–9].
As a result, the precise role of RSV infection in the de-
velopment of allergic disease in children is not clear.
Allergic asthma is a Th2-associated airway inflam-
mation, characterized by the infiltration of eosinophils
and the production of interleukin (IL)–4, IL-5, and IL-
13 by T lymphocytes in response to certain antigens
[10, 11]. In contrast, RSV infection predominantly in-
duces a Th1 immune response, which is characterized
by the production of IL-12 and interferon (IFN)–g [12,
13]. We [14] and other researchers [15] have previously
demonstrated in a mouse model of allergic asthma that
RSV infection, when induced during the provocation
phase of exposure to allergens, aggravates the conse-
quences of airway sensitization to and challenge with
ovalbumin (OVA), resulting in enhanced pulmonary ex-
pression of Th2 cytokines, allergy-associated lung patho-
logic lesions, and AHR. In addition, the RSV-induced
Th1 response remains unchanged [14].
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Figure 1. Study design. A, To investigate the influence of the timing of inoculation with respiratory syncytial virus (RSV) on RSV-enhanced ovalbumin
(OVA) allergy, OVA-sensitized and -challenged BALB/c mice received 107 pfu of RSV on day 0, 7, 20, 30, or 35 (arrows). B, To examine the influence
of prior inoculation with RSV on RSV-enhanced OVA allergy, OVA-sensitized and -challenged mice received pfu of RSV on days 0 and 35.71.5 10
inl, Intranasal; ip, intraperitoneal.
The results of several studies have suggested that the time
between infection and exposure to allergens may be critical in
determining whether viral [16, 17] or bacterial [18] infection
will influence the development of respiratory allergy in mice.
To gain more insight into the mechanisms of RSV-enhanced
OVA allergy, we investigated whether the timing of inoculation
with RSV (i.e., before or during the period of sensitization to
and challenge with the allergen) determines the outcome of
allergic disease in mice.
As mentioned above, most children become infected with RSV
during their first or second year of life [3]. Because immunity
against RSV is only partial, reinfections can occur throughout
life [2]. This means that an RSV infection that occurs shortly
before or during challenge with an allergen might have been
preceded by prior RSV infections (i.e., before sensitization to an
allergen). The individual’s history of RSV infection could mod-
ulate viral replication and the immune response during a second
RSV infection, thus influencing its potential effect on respiratory
allergy. Whether prior infection with RSV enhances or protects
against RSV-enhanced OVA allergy needs to be investigated. In
the present study, we therefore inoculated mice with RSV before
sensitization to and challenge with OVA and reinfected them
during the challenge with OVA. The cytokine and inflammatory
data obtained from the experiments presented here lead to a
better understanding of the mechanism by which RSV infection
affects respiratory allergy.
MATERIALS AND METHODS
Virus. Human RSV stock A2 (RSV A2) was obtained from
the American Type Culture Collection (ATCC). The virus was
cultured on HEp-2 cells (ATCC) in RPMI 1640 medium (Gibco
BRL, Life Technologies) containing 10% heat-inactivated fetal
calf serum (Greiner), 2 mmol/L glutamine, 100 IE/mL peni-
cillin, and 100 U/mL streptomycin, as described elsewhere [19].
The virus inoculum contained pfu of RSV/mL, as as-83 10
sessed by use of a quantitative plaque-forming assay [19].
Mice. Female BALB/c mice were obtained from Harlan
Olac and were used at 6–10 weeks of age. One week before the
experiments started, mice belonging to 1 treatment group (n
p6) were housed together in 1 cage, according to the exper-
imental set-up in a temperature-controlled animal room. Mice
were kept in a 12-h light/dark cycle in pathogen-free conditions
and received food and water ad libitum. The committee on
animal welfare of the Dutch National Institute of Public Health
and the Environment approved the study.
Experimental design. Mice were sensitized to OVA by in-
traperitoneal (ip) administration of 0.5 mL of OVA (Grade II;
Sigma-Aldrich) (20 mg/mL OVA in saline) for 7 times on every
other day starting at day 0. From day 33 through day 40, mice
were challenged with aerosol OVA (2 mg/mL of saline) for 5
min on 8 consecutive days [14, 20].
To examine the influence of the time point of inoculation
with RSV during the sensitization/challenge protocol, OVA-sensi-
tized mice were inoculated intranasally (inl) with RSV (1.5
107 pfu in 50 mL) at different time points, according to the
schedule shown in figure 1A. The infected mice were compared
with OVA-allergic mice inoculated with uninfected culture ly-
sate (mock) at the same time point. To investigate the influence
of prior inoculation with RSV on RSV-enhanced allergy, 1
group received pfu of RSV on both day 0 and day 3571.5 10
of the experimental protocol (figure 1B). Before inoculation,
mice were anesthetized with halothane. RSV-enhanced lesions
are best analyzed at day 43 of the experimental protocol (day
3 after the last challenge with OVA) [14]; therefore, on that
day, mice were anesthetized ip with Ketamine Rompun (xy-
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lazine; Bayer Benelux) Atropine and killed. Blood was obtained
via orbital puncture. The lungs were removed. The right lung
was snap-frozen in liquid nitrogen and stored until processed
further. The left lung was intratracheally fixed with formalin
and immersed in fixative.
Histopathologic examination. Formalin-fixed lungs were
embedded in paraplast (Monoject). Transverse sections of 5 mm
were stained with hematoxylin-eosin. In a blinded fashion, an
independent observer examined the slides for peribronchiolitis
(i.e., infiltration of inflammatory cells in the peribronchiolar
space), alveolitis (i.e., infiltration of inflammatory cells in the
alveolar wall), perivasculitis (i.e., infiltration of inflammatory
cells in the perivascular space), hypertrophy of mucus-pro-
ducing glands, and eosinophilia. Lung lesions were scored semi-
quantitatively as absent (0), minimal (1), slight (2), moderate
(3), marked (4), or severe (5).
Isolation of RNA and reverse-transcriptase (RT) polymerase
chain reaction (PCR). Total cellular RNA was isolated from
frozen lung samples by use of Trizol Reagent (GibcoBRL, Life
Technologies). Ten microliters of total lung RNA was reverse
transcribed, and cytokine PCRs (IL-4, IL-5, IL-13, IFN-g, and
IL-12) of the cDNA were performed as described elsewhere
[12]. Eotaxin RT-PCR was performed according to the same
protocol as that used for the cytokine RT-PCRs, using sense
(5′-CCCCAACACACTACTGAAGA-3′) and antisense (5′-CTA-
CATGAAGCCAAGTCCTT-3′) primers. To prevent interassay
variation, PCRs of all samples from 1 experiment were done
simultaneously and were loaded on the same agarose gel for
quantification. Band intensities were analyzed by use of the
Molecular Analyst software system (Bio-Rad Laboratories). All
results were corrected for mRNA content of the sample by use
of b-actin mRNA as a standard. b-Actin mRNA was amplified
by use of the mouse control amplifier set (Clontech), according
to the manufacturer’s protocol. For quantification of the RSV
load in lung tissue, RT-PCR was performed with RSV F-pro-
tein–specific primers (upper primer, 5′-TTAACCAGCAAAGT-
GTTAGA-3′; lower primer, 5′-TTTGTTATAGGCATATCATTG-
3′), as described elsewhere by Paton et al. [21]. The PCR product
was analyzed by detecting the band intensities on the agarose
gel by use of the Molecular Analyst software system (Bio-Rad
Laboratories).
IgE antibodies in serum. Total and OVA-specific IgE an-
tibodies in serum were determined by use of a modified capture
ELISA, according to the protocol of van Halteren et al. [22].
As coating antibody, rat anti–mouse IgE monoclonal antibody
EM-95 was used [23]. Total IgE was detected by use of bio-
tinylated rat anti–mouse IgE (Pharmingen). Total concentra-
tions of IgE were calculated by interpolation from a standard
titration curve with known concentrations of recombinant
mouse IgE (Pharmingen). The detection limit of the total IgE
assay was 900 pg/mL. OVA IgE was detected with digoxigenin-
coupled OVA. OVA-specific IgE levels were expressed as the op-
tical density at 490 nm (OD490) of a 1:32 diluted serum.
Statistical analysis. Data are presented as .mean SEM
Statistical significance was determined for differences in cyto-
kine ratios and IgE concentrations by use of the Student’s t
test (Excel; Microsoft) and for differences in histological scores
by use of the nonparametric Wilcoxon test (SAS; SAS Institute).
RESULTS
Influence of RSV inoculation time point on respiratory allergy.
We previously observed that inoculation with RSV, when per-
formed during challenge with OVA, enhances OVA-induced
pulmonary infiltration of inflammatory cells and expression of
IL-4, IL-5, and IL-13 mRNA [14]. In the present study, we
examined whether the timing of inoculation during sensitiza-
tion to and challenge with the allergen is critical. Mice were
therefore inoculated with RSV before or during sensitization
to OVA and before or during challenge with OVA (figure 1A).
As shown in figure 2, RSV enhanced the expression of IL-
4 and IL-13 mRNA in lung tissue of OVA-allergic mice only
when inoculation was performed shortly before (day 30) or
during (day 35) challenge with OVA, compared with OVA/
mock-treated control mice. In addition, inoculation with RSV
at all 3 time points after sensitization to OVA (days 20, 30, and
35) enhanced pulmonary expression of IL-5 mRNA in OVA-
allergic mice. Simultaneous with the enhanced expression of
Th2 cytokine mRNA, inoculation with RSV after sensitization
to OVA (day 20, 30, or 35) induced enhanced expression of
IFN-g and IL-12 mRNA in OVA-allergic mice, compared with
OVA/mock-treated control mice (figure 2). In addition, pul-
monary expression of IL-4, IL-13, and IFN-g mRNA was sig-
nificantly higher in allergic mice inoculated on day 30 or 35,
compared with the other time points of inoculation with RSV.
In parallel with the increased expression of Th2 cytokine
mRNA, RSV enhanced hypertrophy of mucus-producing epi-
thelial cells only when inoculation was performed shortly before
(day 30) or during (day 35) challenge with OVA, compared
with OVA/mock-treated control mice. Likewise, the alveolar
inflammation was significantly increased, compared with OVA/
mock-treated control mice, only when inoculation with RSV
was performed on day 20, 30, or 35. In addition, alveolitis and
hypertrophy of mucus-producing epithelial cells were signifi-
cantly enhanced in lungs of allergic mice inoculated with RSV
on day 35, compared with the other time points of inoculation
with RSV. In contrast, no relationship between increased levels
of Th2 cytokines and peribronchiolar and perivascular inflam-
mation was observed. Finally, pulmonary eosinophilic infiltra-
tion could only be observed in OVA-allergic mice inoculated
with RSV on day 35. However, there was no difference between
the OVA/mock- and OVA/RSV-treated mice, indicating that
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Figure 2. Relative expression against b-actin of lung interleukin (IL)–4, IL-5, IL-13, interferon (IFN)–g, and IL-12 mRNA, determined at day 43 of
the experimental protocol (i.e., day 3 after the last challenge with ovalbumin [OVA]). Mice were inoculated with respiratory syncytial virus (RSV) at
different time points during sensitization to and challenge with OVA (black bars). Control mice were inoculated with mock virus at the corresponding
time points (hatched bars). Mean ( /group) are depicted. * , OVA/RSV- vs. OVA/mock-treated mice. # , OVA-treatedvalues SEM np 6 P ! .05 P ! .05
mice inoculated with RSV at different time points.
inoculation with RSV did not affect OVA-induced eosinophilia
in the present study. The lung pathologic lesions of OVA-sen-
sitized and -challenged mice inoculated with RSV on day 35
is illustrated in figure 3.
To further elucidate the influence of RSV infection on OVA
allergy, total and OVA-specific IgE levels were determined in
serum at day 43 of the experimental protocol. Sensitization to
and challenge with OVA resulted in the production of OVA-
specific IgE in serum. As demonstrated elsewhere [14], inoc-
ulation with RSV during challenge with OVA did not increase
the production of total and OVA-specific IgE, compared with
the corresponding OVA/mock-treated mice (data not shown).
However, inoculation with RSV on day 35 was associated with
significantly higher levels of both total ( mg/mL) and2.10 0.45
OVA-specific IgE (OD490 of ), compared with in-1.284 0.092
oculation on day 0 (total IgE, mg/mL; OVA-specific0.66 0.12
IgE, OD450 of ) or day 30 (total IgE, 0.770.210.698 0.176
mg/mL; OVA- specific IgE, OD450 of ). However,0.559 0.134
the same dependence on time was observed after mock inoc-
ulation (data not shown).
Influence of prior inoculation with RSV on RSV-enhanced
OVA allergy. We subsequently examined whether prior in-
oculation with RSV could diminish the effects of RSV on OVA
allergy. We therefore compared the cytokine and inflammatory
responses of OVA-allergic mice inoculated on day 35 (during
challenge with OVA) with those of identically treated mice in-
oculated inl with live RSV on day 0 of the experimental protocol
(figure 1B). To examine whether prior inoculation with RSV
influences viral replication after reinfection, the RSV load in
lung tissue was examined, by use of RT-PCR, at day 43 of the
experimental protocol (i.e., day 8 after inoculation). We ob-
served that prior inoculation with RSV (on day 0) significantly
decreased the virus load. The virus load was 8 times lower in
previously inoculated mice, indicating that prior inoculation
with RSV diminished viral replication after reinfection (data
not shown).
As demonstrated above, inoculation with RSV during chal-
lenge with an allergen enhanced the expression of the Th2
cytokines in lungs of OVA-allergic mice (figure 2). However,
prior inoculation with RSV did not abrogate this effect (figure
4, left). In addition, prior inoculation with RSV did not sig-
nificantly diminish the pulmonary expression of IFN-g and IL-
12 mRNA in OVA/RSV-treated mice (figure 4, left).
In contrast, prior inoculation with RSV diminished the al-
veolitis (from marked to minimal) and hypertrophy of mucus-
producing epithelial cells (from marked to moderate) in lungs
of OVA/RSV-treated mice (figure 4, right). However, peribron-
chiolar and perivascular inflammation in OVA/RSV-treated
mice was not influenced by prior inoculation with RSV (figure
4, right). In addition, no significant reduction of the eosino-
philic infiltration was observed (figure 4, right).
As mentioned above, no change in levels of total or OVA-
specific IgE was measured in OVA-allergic mice inoculated with
RSV on day 35, compared with control mice. Nevertheless,
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Figure 3. Lung section of ovalbumin (OVA)–sensitized and -challenged
mouse inoculated with respiratory syncytial virus (RSV) on day 35. Lung
pathologic lesions were analyzed at day 43 of the experimental protocol
(i.e., day 3 after the last challenge with OVA). A marked hypertrophy of
mucus-producing cells in bronchiolar epithelium was observed (arrow-
head), together with perivascular infiltration of eosinophils (arrows) and
lymphocytes (original magnification, 1200).
prior inoculation with RSV decreased the concentration of both
total ( ) and OVA-specific IgE ( ) in serum of OVA/P ! .05 P ! .001
RSV-treated mice, to approximately one-third of the concentra-
tion in serum of OVA/RSV-treated mice that were not previously
inoculated with RSV (data not shown).
DISCUSSION
Results from different epidemiological studies in which the
association between RSV infection in infancy and the devel-
opment of respiratory allergy later in life was investigated have
been inconclusive [4, 7]. In addition to epidemiological studies,
studies using mouse models have investigated the mechanisms
through which RSV infection influences the allergic immune
response. We previously demonstrated, in a mouse model of
allergic asthma, that RSV infection exacerbates the allergic Th2
cytokine response and lung pathologic lesions [14], whereas
RSV infection in nonallergic mice did not induce a significant
pulmonary Th2 cytokine response [12, 14]. In the present study,
we have shown that the timing of RSV infection is critical for
RSV-enhanced allergic responses. RSV infection enhanced the
pulmonary Th2 cytokine response only when mice were in-
oculated after sensitization to OVA. The increased Th2 cytokine
mRNA responses coincided with increased alveolitis and hy-
pertrophy of mucus-producing epithelial cells. Since both al-
veolitis and pulmonary expression of IFN-g mRNA are spe-
cifically enhanced by RSV infection [12], the enhanced alveolitis
is likely a result of the effect of RSV alone, not RSV-enhanced
allergy. Therefore, only the hypertrophy of mucus-producing
cells seems to be related to increases in expression of Th2 cy-
tokines. In contrast to the other parameters of allergic inflam-
mation, perivasculitis and peribronchiolitis were not dependent
on timing of inoculation with RSV, indicating that they were
likely not correlated with elevated levels of pulmonary expres-
sion of Th2 cytokine mRNA. Because IL-5 has been identified
as an eosinophil attractant [24, 25], and, because we observed
high levels of expression of IL-5 mRNA in OVA-treated mice
inoculated with RSV on day 35, we expected to see increased
eosinophilia. A possible explanation for the absence of aggravated
eosinophilia could be that the moment of examination was too
late and that eosinophilia was already in decline [26]. Further-
more, Hessel et al. observed, in an identical mouse model of
allergic asthma, that AHR (one of the key characteristics of
asthma) can develop without the presence of eosinophils in the
lung [20, 27]. We did not measure hyperreactivity of the airways,
but we did observe a moderate hypertrophy of mucus-producing
glands in allergic mice, which was enhanced even after inocu-
lation with RSV. Increased production of mucus in the airways
is reported to contribute to the development of AHR [28].
In contrast to the observation that inoculation with RSV
before sensitization to and challenge with OVA did not influ-
ence the allergic responses in lung tissue, Peebles et al. dem-
onstrated decreased AHR and production of pulmonary IL-13
protein in mice receiving a comparable treatment [29]. Since
Peebles et al. also found that AHR and production of Th2
cytokines are not always correlated, these different observations
do not have to be in conflict [30]. It is possible that factors
other than Th2 cytokines could explain such observations.
A possible explanation for the time-dependent effect of RSV
infection on OVA allergy, as observed in the present study, may
be the OVA-induced cytokine milieu. Among antigen-present-
ing cells, dendritic cells (DCs) play a central role in regulating
the cellular immune response and T cell polarization [31]. The
outcome of T cell polarization by DCs can be either Th1 or
Th2, depending on the microenvironment and the character
of pathogen-induced inflammatory reactions [32]. In the model
of sensitization to and challenge with OVA, a Th2 cytokine
environment is induced by sensitization to OVA of lung tissue
of mice. In this environment, presentation of RSV by DCs to
T cells might stimulate T cells to become Th2 cells, aggravating
the Th2 response. Coyle et al. [33] demonstrated in vivo (mice)
and in vitro that production of IL-4 by OVA-specific CD4+ T
cells switches the virus-specific CD8+ T cells in the lung to
produce IL-5. These results indicate that the virus-specific im-
mune response could be modified by a local, allergen-induced
Th2 immune response. When inoculation with RSV is per-
formed before or during sensitization to the allergen, no Th2
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Figure 4. Relative expression against b-actin of lung interleukin (IL)–4, IL-5, IL-13, interferon (IFN)–g, and IL-12 mRNA (left) and severity scores
of pulmonary lesions (right), examined at day 43 of the experimental protocol (i.e., day 3 after the last challenge with ovalbumin [OVA]). OVA-sensitized
and -challenged mice were inoculated with respiratory syncytial virus (RSV) on day 35 of the OVA-challenge period and were (hatched bars) or were
not (black bars) inoculated with RSV on day 0 of the experimental protocol. Indicated pulmonary lesions are scored from absent (0) to severe (5).
Mean ( /group) are depicted. Statistical differences between differently treated groups are analyzed by use of the Students tvalues SEM np 6
test for mRNA expression data or the nonparametric Wilcoxon’s test for histopathologic scores. * .P ! .05
cytokine environment is present yet, which might result in
failure to enhance the Th2 response.
In addition to the influence of the time of inoculation on
the allergic inflammation, a high background for expression of
IL-5 and IL-13 mRNA was observed in the lungs of mice in-
oculated with mock or RSV before sensitization to OVA. The
reason for this high background is unclear. Nevertheless, be-
cause the RSV and mock inocula differ only in RSV content
(since there is no RSV in the mock inoculum) significant dif-
ferences between the RSV and mock groups must be specifically
induced by RSV.
Epidemiological data show that almost all children become
infected with RSV during the first or second year of life [3]
and that reinfections with RSV occur throughout life. This
phenomenon means that an RSV infection shortly before or
during challenge with OVA might have been preceded by an
earlier RSV infection before sensitization to the allergen. We
have demonstrated that prior inoculation with RSV did not
change the pulmonary expression of cytokine mRNA in allergic
mice inoculated with RSV during challenge with OVA. Like
expression of Th2 cytokine mRNA, peribronchiolar and peri-
vascular inflammation and eosinophilia are not altered by prior
inoculation with RSV. These results are in accordance with
those of Peebles et al., who observed that inoculation with RSV
before sensitization to the allergen has no effect on levels of
IL-4 and IL-5 protein in the lungs of OVA/RSV-treated mice
[34]. However, they found that inoculation with RSV protected
against RSV-enhanced AHR. In the present study, prior inoc-
ulation with RSV diminished hypertrophy of mucus-producing
cells in OVA-allergic mice infected with RSV. Taken together,
these results suggest that increased hypertrophy of mucus-pro-
ducing cells is related to enhanced AHR. In line with the results
of previous studies [12, 34], prior inoculation with RSV dra-
matically diminished the virus load after secondary infection,
indicating protection against viral replication. Prior inoculation
with RSV also diminished alveolitis after secondary infection.
This decreased alveolitis is probably due to the absence of RSV
replication after prior inoculation, since alveolitis is specifically
induced by RSV infection [12]. It is still unclear which factors
are responsible for RSV-enhanced allergy. However, the lack of
correlation between virus load and enhancement of allergy in-
dicates that the antiviral inflammatory response, rather than
virus-induced lesions, is responsible for allergy enhancement.
In summary, the timing of inoculation with RSV during
sensitization to and challenge with OVA is critical for the de-
velopment of allergic responses in mice. Increased pulmonary
expression of Th2 cytokine mRNA and hypertrophy of mucus-
producing cells were observed only when mice were inoculated
with RSV after sensitization to OVA. Despite strongly reduced
viral replication, previous inoculation with RSV could not ab-
rogate the RSV-enhanced, OVA-induced expression of Th2 cy-
tokines in the lungs. These data provide evidence that a pre-
existing Th2 cytokine milieu leads to RSV-enhanced respiratory
allergy. In addition, prior inoculation with RSV is only partially
beneficial for later RSV-enhanced respiratory allergy.
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